Login to Your Account

Roche Gains U.S. Approval Of Pegasys For Treating Hepatitis C

By Kim Coghill

Friday, October 18, 2002
Hoffmann-La Roche Inc. received FDA clearance to sell Pegasys, a pegylated interferon for the treatment of hepatitis C, making it the second drug on the market for this disease developed using technology designed to improve circulation time in the body. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription